Neurotrophic factors are endogenous proteins that support the survival, development, and function of neurons. These molecules represent promising therapeutic approaches for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). This page covers the main neurotrophic factors, their signaling mechanisms, therapeutic delivery strategies, and current clinical development[1][2].
Neurotrophic factors bind to specific receptor tyrosine kinases (Trks) or p75 neurotrophin receptor (p75NTR) to activate downstream signaling pathways that promote neuronal survival, synaptic plasticity, and neurogenesis. Key neurotrophic factors include:
In neurodegenerative diseases, neurotrophic factor signaling becomes impaired, contributing to synaptic loss and neuronal death[3].
Neurotrophic factors activate multiple downstream signaling cascades:
Alzheimer's Disease: BDNF levels are reduced in AD brains, correlating with cognitive decline. BDNF signaling impairment contributes to synaptic dysfunction and hippocampal atrophy[4].
Parkinson's Disease: GDNF protects dopaminergic neurons in the substantia nigra. Reduced GDNF signaling is implicated in PD pathogenesis.
Amyotrophic Lateral Sclerosis: BDNF, GDNF, and NT-3 support motor neuron survival. ALS models show impaired neurotrophin signaling.
Huntington's Disease: BDNF transport and signaling are disrupted in HD. Restoring BDNF improves phenotype in animal models.
| Factor | Delivery Method | Challenges | Clinical Status |
|---|---|---|---|
| BDNF | Intranasal, intraventricular, intravenous | Short half-life, BBB penetration | Phase 1/2 trials |
| GDNF | Intraputaminal infusion, AAV delivery | Invasive surgery, diffusion limits | Phase 2 trials |
| NGF | Encapsulated cell implantation, intranasal | Off-target effects, dosing | Phase 2 trials |
| NT-3 | AAV gene therapy | Immune response | Preclinical |
Small molecules that activate Trk receptors offer oral bioavailability advantages:
These compounds cross the BBB and activate downstream signaling without exogenous protein delivery[5].
AAV-mediated gene delivery enables sustained neurotrophic factor expression:
| Agent | Target | Disease | Phase | Status |
|---|---|---|---|---|
| AAV2-GDNF | GDNF | PD | Phase 2 | Completed |
| CERE-110 (AAV2-NGF) | NGF | AD | Phase 2 | Completed |
| BDNF | BDNF | AD | Phase 1 | Recruiting |
| 7,8-DHF | TrkB agonist | AD/PD | Preclinical | IND enabling |
| NTRX-07 | TrkB agonist | AD | Phase 1 | Completed |
Blood-Brain Barrier Penetration: Large molecule delivery remains problematic; intranasal, convection-enhanced delivery, and AAV approaches are being developed[6]
Dosing and Distribution: Achieving therapeutic concentrations in target brain regions without off-target effects
Receptor Specificity: Pan-Trk agonists vs. selective TrkA/B/C agonists
Long-term Expression: Gene therapy provides sustained delivery but raises immunogenicity concerns
Neurotrophic factor therapies may be combined with:
Mandel 2018, Neurotrophic factors in the treatment of neurodegenerative diseases. 2018. ↩︎
Nagahara & Tuszynski 2011, Potential therapeutic uses of BDNF in neurological and psychiatric disorders. 2011. ↩︎
Connor & Dragunow 2015, The role of neuronal growth in neurodegenerative disorders. 2015. ↩︎
Lin 2019, Small molecule TrkB agonists for treating neurological disorders. 2019. ↩︎
Kordower 2013, Neurotrophic factor therapy for Parkinson's disease. 2013. ↩︎